StockData

Harmony Biosciences vs PTC Therapeutics

HRMY and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HRMY and PTCT compare

PTC Therapeutics is the larger company, worth 2.6 times as much as Harmony Biosciences ($5.0B against $1.9B).

Harmony Biosciences grew revenue faster over the last twelve months (24.3% versus −35.1% for PTC Therapeutics).

Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −9.2% at PTC Therapeutics.

Harmony Biosciences scores higher on the StockData Score (18 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHRMYPTCT
Size and price
Market cap$1.9B$5.0B
Share price$33.01$60.36
Change, 1 year−3.0%−19.8%
Change, 5 years−12.1%58.6%
Beta (5Y)1.111.09
Employees293991
StockData Score
Total score18 (better)5
Valuation score6 (better)1
Growth score2 (better)1
Performance score4 (better)2
Health score6 (better)1
Dividend score00
Valuation
P/E10.7×–
P/S2.0× (better)4.4×
P/B1.9×–
EV/EBITDA6.1× (better)16.5×
P/FCF–2440×
FCF yield–0.04%
Fair value$53.99$47.05
Margin of safety38.9% (better)−28.3%
Growth
Revenue growth (TTM)24.3% (better)−35.1%
Revenue growth, 5Y average40.3% (better)35.4%
Net income growth (TTM)0.20% (better)−114%
EPS growth (TTM)−0.32% (better)−114%
Profitability
Gross margin75.4%–
Operating margin24.0% (better)12.8%
Net margin18.9% (better)−9.2%
FCF margin–0.18%
Return on equity20.5%–
Return on invested capital40.1%–
Financial health
Debt / equity0.15–
Net debt / EBITDA−2.23−7.63
Interest coverage17.1×–
Current ratio3.48 (better)3.27
Altman Z-score5.12 (better)0.78
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.0%120%
Held by insiders12.1%3.0%
Insider net buying, 12 months−$5.8M (better)−$44.2M
Short interest, % of float13.0%9.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.